• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by uniQure N.V.

    4/28/25 6:03:12 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    DEFA14A 1 qure-20250611xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (RULE 14A-101)

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    ​

    UNIQURE N.V.

    (Name of Registrant as Specified in Its Charter)

    ​

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

    ​


    GRAPHIC

    www.investorvote.com/QURE Step 1: Go to www.investorvote.com/QURE. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/QURE or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 0455EA Important Notice Regarding the Availability of Proxy Materials for the uniQure N.V. Annual General Meeting to be Held on June 11, 2025 Under U.S. Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual general meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual general meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 proxy statement and 2024 annual report is available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 30, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. uniQure N.V. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by June 10, 2025 at 9:59 P.M., Central European Summer Time.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/QURE. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials uniQure N.V.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 30, 2025. uniQure N.V.’s Annual General Meeting of Shareholders will be held on Wednesday June 11, 2025 at Paasheuvelweg 25a, 1105 BP Amsterdam, the Netherlands, at 9:00 AM Central European Summer Time. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR Proposals 1-11: 1. Adoption of the 2024 Dutch statutory annual accounts for the fiscal year ended December 31, 2024. 2. Discharge of liability of the members of the Board for their management during the fiscal year ended December 31, 2024. 3. Reappointment of Robert Gut, M.D., Ph.D. as non-executive director. 4. Reappointment of Matthew Kapusta as executive director. 5. Reappointment of Jeremy Springhorn, Ph.D. as non-executive director. 6. Authorization of the Board as the competent body to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares. 7. Authorization of the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares. 8. Authorization of the Board to repurchase Ordinary Shares. 9. Appointment of KPMG as external auditor of the Company for the financial year 2025. 10. Approval, on an advisory basis, of the compensation of the named executive officers of the Company. 11. Resolution to adopt the Amendment and Restatement of the 2014 Share Incentive Plan. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Shareholder Meeting Notice

    Get the next $QURE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    10/27/2021$66.00Outperform
    William Blair
    More analyst ratings

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

      ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

      6/11/25 8:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

      ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis

      6/2/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

      ~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a clinical case study of the first participant dosed in the first cohort of its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, in patients with refractory MTLE. The data are being

      5/29/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on uniQure with a new price target

      Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

      4/1/25 8:05:22 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure upgraded by Raymond James

      Raymond James upgraded uniQure from Outperform to Strong Buy

      12/10/24 11:36:55 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on uniQure with a new price target

      Raymond James resumed coverage of uniQure with a rating of Outperform and set a new price target of $20.00

      10/10/24 8:37:20 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    SEC Filings

    See more

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $QURE
    Financials

    Live finance-specific insights

    See more

    $QURE
    Leadership Updates

    Live Leadership Updates

    See more

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • uniQure N.V. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      6/13/25 5:27:13 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      6/2/25 8:25:16 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by uniQure N.V.

      SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

      5/15/25 8:00:10 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Post Leonard E was granted 7,970 units of Ordinary Shares, increasing direct ownership by 33% to 32,049 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/13/25 5:07:11 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kaye Jack was granted 7,970 units of Ordinary Shares, increasing direct ownership by 55% to 22,551 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/13/25 5:01:15 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jacques Rachelle Suzanne was granted 7,970 units of Ordinary Shares, increasing direct ownership by 35% to 30,458 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/13/25 4:55:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

      ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis

      6/2/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

      ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~         ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached agreement

      12/10/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

      ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

      6/11/25 8:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

      NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

      5/19/25 8:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

      LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

      6/26/23 7:11:42 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/14/24 12:01:42 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/13/24 4:05:14 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/25/24 9:48:27 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care